Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model.

摘要: Spontaneously occurring soft tissue sarcoma (STS) is relatively common in canine cancer patients. Because of the similarities to human disease, STSs are a valuable and readily available resource for study new therapeutics. In this study, patient-derived xenograft (PDX) model, CDX-STS2, was established. The CDX-STS2 model engrafted expanded systemic administration studies with chemotherapeutic agents commonly used treat STS, including doxorubicin, docetaxel gemcitabine. Immunohistochemistry drug-specific biomarkers tumour growth measurement revealed sensitivity doxorubicin docetaxel, whereas gemcitabine had no effect on growth. Although many PDX models have been established, few reported date. represents STS research origin that will be useful bridging preclinical clinical pet dogs.